Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-01-06
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage TechBio company that uses automated wet labs, multimodal data, and machine learning to discover and develop small-molecule medicines and partnered programs.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

From milestone biotech to repeatable TechBio revenue
A credible re-rate requires repeatable clinical translation plus a shift toward predictable platform revenue. The setup is asymmetric, but success depends on 2026–2028 data quality and capital discipline.

Analysis

Thesis
If the new CEO converts Recursion OS + Exscientia-enabled chemistry into repeatable clinical proof and more predictable platform revenue (not just milestones), RXRX can re-rate from “catalyst biotech” to a scaled platform biotech by 2031.
Last Economy Alignment
Strong fit: it industrializes cognition-heavy discovery via data+automation+compute, and its partnership network can compound learning faster than traditional R&D orgs.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.1x (from 5 most recent analyses)
Reasoning
The upside case is a business-model shift: partner-funded discovery plus a small number of internally owned assets that reach true commercial value. If Recursion proves it can repeatedly turn its data/automation loop into clinical candidates and packages parts of the stack into repeatable enterprise purchases, the market will likely value it closer to platform-like peers rather than a single-asset biotech.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The dominant risk is clinical translation: without clean, decision-grade efficacy/safety signals in 2026–2028, the platform will be viewed as a costly R&D engine rather than a compounding asset. Second-order risks are funding/dilution (given burn), partner revenue lumpiness, and competitive convergence as more teams build end-to-end AI-native discovery stacks.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.14
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case